Emerging evidence suggests that metabolic disorders and systemic inflammation can directly impact cognitive function and neurodegenerative risk. These insights are reshaping how we think about brain health and helping to rewrite the playbook for how we approach neurodegenerative disease.
Some of this has stemmed from the recent rapid uptake in medications designed to address obesity, such as glucagon-like peptide-1 receptor (GLP-1R) agonists. They are also showing neurological benefits, restoring metabolic balance, and dampening inflammation. As a result, we are beginning to observe parallel improvements in brain health and gain a greater understanding of the role of GLP and other secretin receptors, such as gastric inhibitory polypeptide receptor (GIPR) and glucagon receptor (GcgR), in neurological health.
This confluence of metabolic and brain science is stimulating new research paths, including the investigation and repurposing of diabetes and weight management drugs to target inflammatory pathways in neurodegenerative disorders like Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS).
Neuroinflammation: A double-edged sword in brain health
Neuroinflammation is the brain’s built-in defense mechanism—an immune response designed to protect neural tissue from pathogens, injury, and stress. However, a chronic inflammatory state can contribute to the onset and progression of neurodegenerative diseases. Persistent neuroinflammation is marked by elevated levels of pro-inflammatory cytokines like IL-6, TNF-α, and IL-1β and increased oxidative stress, which can accelerate neuronal damage.
Beyond the brain, a strong connection between systemic inflammation and neurodegeneration is supported by increasing levels of evidence. For example, chronic diseases like diabetes, obesity, atherosclerosis, and depression, all associated with chronic inflammation, are known to increase the risk of developing neurodegeneration. Even aging is accompanied by a low-grade systemic inflammation, termed “inflammaging,” further emphasizing inflammation's role as an initiator and promoter of neurodegenerative diseases.
Obesity and neurodegeneration: A systemic inflammatory link
Obesity, in particular, is linked to chronic, low-grade, systemic inflammation. Adipose tissue, particularly visceral fat, acts as an active endocrine organ and consistently produces a variety of pro-inflammatory cytokines like TNF-α and IL-6, adipokines such as leptin and resistin, and free fatty acids. This pro-inflammatory environment contributes to insulin resistance and other metabolic disorders. In addition, pro-inflammatory cytokines can disrupt the blood-brain barrier, enter the brain, and induce persistent chronic neuroinflammation, contributing to cognitive decline and neurodegeneration.
The link between obesity and neurodegenerative diseases is also backed by evidence showing a strong correlation between obesity and the development of AD and PD. Obesity (BMI >30 kg/m2) even in midlife significantly increases the risk of dementia and AD later in life, and the combination of obesity, high total cholesterol, and high systolic blood pressure increases the risk of dementia by approximately six times. Obesity has also been linked to a decline in brain volume and brain atrophy in cognitively normal older adults.
Insulin resistance in the brain: A catalyst for neurodegeneration
In addition, growing knowledge of secretin receptors, such as GLP-1Rs and GIPRs, is contributing to our understanding of the effects of agonists to these receptors in the brain. Research has revealed they are expressed in the brain in regions such as the hippocampus, hypothalamus, and cerebral cortex and play roles in memory formation, food intake regulation, and inflammation control.
Furthermore, it’s now understood that insulin resistance can occur in the brain and contribute directly to neurodegenerative disease pathology. In AD, even patients without type 2 diabetes show signs of central insulin resistance, including reduced signaling from insulin and insulin-like growth factor-1 (IGF-1) in key neural circuits, which accelerate neuroinflammation and impair memory.
Some researchers have also suggested the term “type 3 diabetes” for AD, suggesting it represents a form of diabetes specifically affecting the brain. Impaired cerebral glucose use is an early AD-related abnormality, leading to the hypothesis that dysfunctional insulin signaling is central to AD, even in the absence of overt diabetes. This insulin dysfunction in the brain can disrupt critical neuronal processes, including memory formation and glucose uptake, and accelerate neuroinflammation.
GLP-1R agonists: beyond metabolism, toward brain health
The growing use of weight management drugs like GLP-1R agonists is also supporting a deeper connection between metabolic dysfunction and brain health. By restoring insulin sensitivity and dampening inflammation, they may help reverse the cognitive decline associated with aging and metabolic syndromes. For example, a systematic review of 26 randomized clinical trials showed that GLP-1s were associated with a 45% reduction in dementia risk among people with type 2 diabetes.
In addition, because of the broad expression of GLP-1R and GIPR within the brain, agonists of these receptors are demonstrating anti-inflammatory effects in the brain in preclinical settings and are being explored in clinical settings, with early results suggesting the importance of the agonist being able to cross the blood-brain barrier.
Translating metabolic insights into neuro breakthroughs
The future of neurological research is increasingly converging with studies on inflammation and metabolic dysfunction, providing a more integrated view of brain health. Rather than isolating neurological diseases as siloed conditions, we’re beginning to examine how metabolic diseases and systemic inflammation can contribute to cognitive decline and neurodegeneration.
With this greater understanding, it’s exciting to think about how future studies can uncover mechanistic links between metabolic pathways and brain health. As a result, metabolic ill-health and inflammation could represent a modifiable risk factor for a number of neurological disorders and offer new pathways for treatment.
To learn about how the Headlands Research network of clinical sites can support your neurological research, contact us today.
About the author
Dr. Linda Pao is a board-certified neurologist with over 25 years of experience in private practice, academic medicine, and clinical research in South Florida. She earned both her undergraduate and medical degrees from Brown University’s seven-year Medical Education Program, completed her neurology residency and EMG fellowship at New England Medical Center in Boston (serving as Chief Resident for two years), and completed a neuromuscular fellowship at Mayo Clinic in Rochester, MN.
Dr. Pao has spent the past two decades specializing in neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and Lewy body dementia. She previously founded the acute stroke program at Jupiter Medical Center and co-directed the MDA Clinic in West Palm Beach. She has served on hospital boards and medical committees across multiple institutions in South Florida.
Currently, Dr. Pao is the Co-Medical Director and a Principal Investigator at JEM Research Institute, where she leads numerous clinical trials as Principal Investigator. A strong advocate for patient education and diversity in research, she is a frequent speaker in the community and media, with a particular interest in the prevention of neurodegenerative conditions.